Micafungin: a therapeutic review

References

• Yamazaki T, Kume H, Murase S, et al. Epidemiology of visceral mycoses: analysis of data in Annual of the Pathological Autopsy cases in Japan. J. Clin. Microbial. 37, 1732–1738 (1999).
   PubMed Web of Science ®Google Scholar
• Singh N. Fungal infections in the recipients of solid organ transplantation. Infect. Dis. Clin. North. Am. 17(1), 113–134, viii (2003).
   PubMed Web of Science ®Google Scholar
• Wakayama M, Shibuya K, Ando T, et al. Deep-seated mycosis as a complication in bone marrow transplantation patients. Mycoses 45, 146–151 (2002).
   Google Scholar
• Tomishima M, Ohki H, Yamada A, et al. FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J. Antibiot. (Tokyo) 52, 674–676 (1999).
   PubMed Web of Science ®Google Scholar
• Iwamoto T, Fujie A, Sakamoto K, et al. WF11899A, B and C, novel antifungal lipopeptides. Taxonomy, fermentation, isolation and physicochemical properties. J. Antibiot. (Tokyo) 47, 1084–1091 (1994).
   PubMed Web of Science ®Google Scholar
• Hatano K, Morishita Y, Nakai T, et al. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fitmigatus. J. Antibiot. (Tokyo) 55, 219–222 (2002).
   PubMed Web of Science ®Google Scholar
• Beaulieu D, Tang J, Yan SB, et al. Characterization and cilofungin inhibition of solubilized Aspergillus fumigatus (1,3)-I3-D-glucan synthase. Antimicrob. Agents. Chemother. 38, 937–944 (1994).
   PubMed Web of Science ®Google Scholar
• Suzuki S, Terakawa M, Yokobayashi F, et al. Pharmacokinetics of FK463, a novel water-soluble echinocandin-like lipopeptide, in animals. 38th Interscience Conference Antimicrob. Agents. Chemother. (1998) (Abstract F144).
   Google Scholar
• Yamato Y, Kaneko H, Yamasaki S, et al. Distribution and excretion after intravenous dosing of C14-micafungin to rats. Jpn J. Chemother. 50, 80–87 (2002).
   Google Scholar
• Azuma J, Nakahara K, Kagoyama A, et al. Pharmacokinetic study of micafungin. Jpn J. Chemother. 50, 155–184 (2002).
   Google Scholar
• Azuma J, Nakahara K, Kagayama A, et al Phase I study of micafungin. Jpn J. Chemother. 50, 104–147 (2002).
   Google Scholar
• Townsend R, Terakawa M, Bekersky I. PK/disposition of 14C-FK463, a novel echinocandin antifungal, in male volunteers. J. Clin. Pharmacol 40, 1048 (2000) (Absract 1017).
   Google Scholar
• Azmuma J, Nakahara K, Kagayama A, et al. Pharmacokinetic study of micafungin in elderly subjects. Jpn J. Chemother. 50, 148–152 (2002).
   Google Scholar
• Townsend R. Pharmacokinetics of micafungin, an echinocandin antifungal, in subjects with severe renal dysfunction. J. Clin. Pharmacol 42, 1054 (2002).
   Web of Science ®Google Scholar
• Townsend R. Pharmacokinetics of micafungin, an echinocandin antifungal, in subjects with modedrate hepatic dysfunction. J. Clin. Pharmacol 42, 1054 (2002).
   Web of Science ®Google Scholar
• Seibel N, Schwartz C, Arrieta A, et al A Phase 1 study to detemine the safety and pharmacokinetics (PK) of FK463 (Echinocandin) in febrile neutropenic pediatric patients. 40th Interscience Conference Antimicrob. Agents Chemother. (2000) (Abstract 1).
   Google Scholar
• Kaneko H, Yamato Y, Hashimoto T, et al. Drug interactions of micafungin in vitro. JpnJ. Chemother. 50, 94–103 (2002).
   Google Scholar
• Townsend R, Hebert M, Wisemandle W, et al. Concomitant pharmacokinetics (PK) of micafungin, an echinocandin antifungal and cyclosporin in healthy volunteers. J. Clin. Pharmacol 42, 1054 (2002).
   Google Scholar
• Townsend R, Hebert M, Wisemandle W, et al. Concomitant pharmacokinetics (PK) of micafungin, an echinocandin antifungal and tacrolimus in healthy volunteers. J. Clin. Pharmacol 42, 1055 (2002).
   Web of Science ®Google Scholar
• Ikeda F, Otomo K, Nakai T, et al. In vitro activity of a new lipopeptide antifungal agent, micafungin against a variety of clinically important fungi. Jpnl. Chemother. 50, 8–19 (2002).
   Google Scholar
• Mikamo H, Sato Y, Tamaya T In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J. Antimicrob. Chemother. 46, 485–487 (2000).
   PubMed Web of Science ®Google Scholar
• •Showed in vitro activities of the agent against many kinds of fungi, compared with conventional antifungal drugs.
   Google Scholar
• Kohn° S, Masaoka T, Yamaguchi H. A multi-center, open-label clinical study of FK463 in patients with deep mycosis in Japan. 41st Interscience Confircnce Antimicrob. Agents Chemother J-834 (2001) (Abstract J–834).
   Google Scholar
• Kohno S. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand. J. Infect. Dis. (In press).
   Google Scholar
• Kohn° S. Clinical features of micafungin (review). Kansensho 33, 39–46 (2003).
   Google Scholar
• Pettengell K, Mynhardt JTK A multicenter study of the treatment of esophageal candidiasis in HIV positive patients. 40th Interscience Confircnce Antimicrob. Agents-Chemother (2000) (Abstract 1104).
   Google Scholar
• van Burik J, Ratanatharathorn V, Lipton J, et al Randamized, double-blind trial of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing haematopoetic stem cell transplant. 41st Interscience Confircnce Antimicrob. Agents Chemother. (2002) (Abstract).
   Google Scholar
• ••Showed that low-dose micafungin preventsfungal infections in patients who received stem cell transplantation.
   Google Scholar
• Powles R. Assessment of maximum tolerated dose (MTD) of micafungin (FK463) in cancer patients undergoing haematopoetic stem cell transplantation. Trends Fung Infict. (2001) (Abstract).
   Google Scholar
• Kohn° S, Maesaki T, Iwakawa J. Synergistic effects of combination of FK463 with amphotericin B: enhanced efficacy in murine model of invasive pulmonary aspergillosis. 40th Interscience Conference Antimicrob. Agents Chemother (2000) (Absract 1684).
   Google Scholar
• ••Suggested that micafungin, with otherantifungal agents, may offer a synergic effect in the treatment of aspergillosis.
   Google Scholar
• Petraitis V, Petraitiene R, Sarafandi AA, et al Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect. Dis. 187, 1834–1843 (2003).
   PubMed Web of Science ®Google Scholar